{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:32:51Z","timestamp":1793503971230,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Integrating magnetic resonance (MR) into radiotherapy planning has several advantages. This report details the clinical implementation of an MR simulation (MR-planning) program for external beam radiotherapy (EBRT) in one of North America's largest radiotherapy programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and materials<\/jats:title>\n                    <jats:p>An MR radiotherapy planning program was developed and implemented at Sunnybrook Health Sciences Center in 2016 with two dedicated wide-bore MR platforms (1.5 and 3.0 Tesla). Planning MR was sequentially implemented every 3\u00a0months for separate treatment sites, including the central nervous system (CNS), gynecologic (GYN), head and neck (HN), genitourinary (GU), gastrointestinal (GI), breast, and brachial plexus. Essential protocols and processes were detailed in this report, including clinical workflow, optimized MR-image acquisition protocols, MR-adapted patient setup, strategies to overcome risks and challenges, and an MR-planning quality assurance program. This study retrospectively reviewed simulation site data for all MR-planning sessions performed for EBRT over the past 5\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From July 2016 to December 2021, 8798 MR-planning sessions were carried out, which corresponds to 25% of all computer tomography (CT) simulations (CT-planning) performed during the same period at our institution. There was a progressive rise from 80 MR-planning sessions in 2016 to 1126 in 2017, 1492 in 2018, 1824 in 2019, 2040 in 2020, and 2236 in 2021. As a result, the relative number of planning MR\/CT increased from 3% of all planning sessions in 2016 to 36% in 2021. The most common site of MR-planning was CNS (49%), HN (13%), GYN (12%), GU (12%), and others (8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Detailed clinical processes and protocols of our MR-planning program were presented, which have been improved over more than 5\u00a0years of robust experience. Strategies to overcome risks and challenges in the implementation process are highlighted. Our work provides details that can be used by institutions interested in implementing an MR-planning program.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-023-02209-4","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T07:04:53Z","timestamp":1675753493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Clinical implementation of magnetic resonance imaging simulation for radiation oncology planning: 5\u00a0year experience"],"prefix":"10.1186","volume":"18","author":[{"given":"Daniel","family":"Moore-Palhares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brige","family":"Chugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Vesprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Symons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten","family":"Myrehaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Stanisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Czarnota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"2209_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1053\/j.seminoncol.2019.07.004","volume":"46","author":"R Pacelli","year":"2019","unstructured":"Pacelli R, Caroprese M, Palma G, et al. Technological evolution of radiation treatment: implications for clinical applications. Semin Oncol. 2019;46:193\u2013201.","journal-title":"Semin Oncol"},{"key":"2209_CR2","doi-asserted-by":"publisher","first-page":"20180505","DOI":"10.1259\/bjr.20180505","volume":"92","author":"IJ Das","year":"2019","unstructured":"Das IJ, McGee KP, Tyagi N, et al. Role and future of MRI in radiation oncology. Br J Radiol. 2019;92:20180505.","journal-title":"Br J Radiol"},{"key":"2209_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jmr.2012.11.024","volume":"229","author":"E Vinogradov","year":"2013","unstructured":"Vinogradov E, Sherry AD, Lenkinski RE. CEST: from basic principles to applications, challenges and opportunities. J Magn Reson. 2013;229:155\u201372.","journal-title":"J Magn Reson"},{"key":"2209_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ajco.13400","volume":"17","author":"M Gundog","year":"2021","unstructured":"Gundog M, Basaran H, Dogan S, et al. MR-guided simulation is superior than FDG\/PET-guided simulation for local control in nasopharyngeal cancer patients treated with intensity-modulated radiotherapy. Asia Pac J Clin Oncol. 2021;17:43\u201351.","journal-title":"Asia Pac J Clin Oncol"},{"key":"2209_CR5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1120\/jacmp.v17i3.6088","volume":"17","author":"AS Korsager","year":"2016","unstructured":"Korsager AS, Carl J, \u00d8stergaard LR. Comparison of manual and automatic MR-CT registration for radiotherapy of prostate cancer. J Appl Clin Med Phys. 2016;17:294\u2013303.","journal-title":"J Appl Clin Med Phys"},{"key":"2209_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ijrobp.2009.06.031","volume":"76","author":"KK Brock","year":"2010","unstructured":"Brock KK. Results of a Multi-Institution Deformable Registration Accuracy Study (MIDRAS). Int J Radiat Oncol. 2010;76:583\u201396.","journal-title":"Int J Radiat Oncol"},{"key":"2209_CR7","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1177\/1533034617735454","volume":"16","author":"EP Pappas","year":"2017","unstructured":"Pappas EP, Alshanqity M, Moutsatsos A, et al. MRI-related geometric distortions in stereotactic radiotherapy treatment planning: evaluation and dosimetric impact. Technol Cancer Res Treat. 2017;16:1120\u20139.","journal-title":"Technol Cancer Res Treat"},{"key":"2209_CR8","doi-asserted-by":"publisher","first-page":"20190161","DOI":"10.1259\/bjr.20190161","volume":"93","author":"RI Johnstone","year":"2020","unstructured":"Johnstone RI, Guerrero-Urbano T, Michaelidou A, et al. Guidance on the use of MRI for treatment planning in radiotherapy clinical trials. Br J Radiol. 2020;93:20190161.","journal-title":"Br J Radiol"},{"key":"2209_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/mp.14695","author":"CK Glide-Hurst","year":"2021","unstructured":"Glide-Hurst CK, Paulson ES, McGee K, et al. Task group 284 report: magnetic resonance imaging simulation in radiotherapy: considerations for clinical implementation, optimization, and quality assurance. Med Phys. 2021. https:\/\/doi.org\/10.1002\/mp.14695.","journal-title":"Med Phys"},{"key":"2209_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s13246-014-0252-2","volume":"37","author":"A Walker","year":"2014","unstructured":"Walker A, Liney G, Metcalfe P, et al. MRI distortion: considerations for MRI based radiotherapy treatment planning. Australas Phys Eng Sci Med. 2014;37:103\u201313.","journal-title":"Australas Phys Eng Sci Med"},{"key":"2209_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/PL00002385","volume":"177","author":"A Fransson","year":"2001","unstructured":"Fransson A, Andreo P, P\u00f6tter R. Aspects of MR image distortions in radiotherapy treatment planning. Strahlenther Onkol. 2001;177:59\u201373.","journal-title":"Strahlenther Onkol"},{"key":"2209_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s00066-021-01776-3","volume":"197","author":"V Meki\u0161","year":"2021","unstructured":"Meki\u0161 V, \u017dager Marciu\u0161 V, Rogina D, et al. Comparison of treatment position with mask immobilization and standard diagnostic setup in intracranial MRI radiotherapy simulation. Strahlenther Onkol. 2021;197:614\u201321.","journal-title":"Strahlenther Onkol"},{"key":"2209_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.radonc.2016.09.018","volume":"121","author":"ES Paulson","year":"2016","unstructured":"Paulson ES, Crijns SPM, Keller BM, et al. Consensus opinion on MRI simulation for external beam radiation treatment planning. Radiother Oncol. 2016;121:187\u201392.","journal-title":"Radiother Oncol"},{"key":"2209_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.prro.2015.06.006","volume":"5","author":"CK Glide-Hurst","year":"2015","unstructured":"Glide-Hurst CK, Kim JP, To D, et al. Four dimensional magnetic resonance imaging optimization and implementation for magnetic resonance imaging simulation. Pract Radiat Oncol. 2015;5:433\u201342.","journal-title":"Pract Radiat Oncol"},{"key":"2209_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13014-017-0854-4","volume":"12","author":"N Tyagi","year":"2017","unstructured":"Tyagi N, Fontenla S, Zelefsky M, et al. Clinical workflow for MR-only simulation and planning in prostate. Radiat Oncol. 2017;12:119.","journal-title":"Radiat Oncol"},{"key":"2209_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.radonc.2021.09.023","volume":"164","author":"AT Price","year":"2021","unstructured":"Price AT, Kennedy WR, Henke LE, et al. Implementing stereotactic accelerated partial breast irradiation using magnetic resonance guided radiation therapy. Radiother Oncol. 2021;164:275\u201381.","journal-title":"Radiother Oncol"},{"key":"2209_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ijrobp.2016.08.006","volume":"96","author":"S Acharya","year":"2016","unstructured":"Acharya S, Fischer-Valuck BW, Mazur TR, et al. Magnetic resonance image guided radiation therapy for external beam accelerated partial-breast irradiation: evaluation of delivered dose and intrafractional cavity motion. Int J Radiat Oncol. 2016;96:785\u201392.","journal-title":"Int J Radiat Oncol"},{"key":"2209_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100727","volume":"6","author":"N Lowrey","year":"2021","unstructured":"Lowrey N, Koch CA, Purdie T, et al. Magnetic resonance imaging for breast tumor bed delineation: computed tomography comparison and sequence variation. Adv Radiat Oncol. 2021;6: 100727.","journal-title":"Adv Radiat Oncol"},{"key":"2209_CR19","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3389\/fonc.2020.01107","volume":"10","author":"ML Groot Koerkamp","year":"2020","unstructured":"Groot Koerkamp ML, Vasmel JE, Russell NS, et al. Optimizing MR-guided radiotherapy for breast cancer patients. Front Oncol. 2020;10:1107.","journal-title":"Front Oncol"},{"key":"2209_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00066-020-01703-y","volume":"197","author":"V Mengling","year":"2021","unstructured":"Mengling V, Bert C, Perrin R, et al. Implementation of a dedicated 1.5\u00a0T MR scanner for radiotherapy treatment planning featuring a novel high-channel coil setup for brain imaging in treatment position. Strahlenther Onkol. 2021;197:246\u201356.","journal-title":"Strahlenther Onkol"},{"key":"2209_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ijrobp.2019.06.2530","volume":"105","author":"D Bird","year":"2019","unstructured":"Bird D, Henry AM, Sebag-Montefiore D, et al. A systematic review of the clinical implementation of pelvic magnetic resonance imaging-only planning for external beam radiation therapy. Int J Radiat Oncol. 2019;105:479\u201392.","journal-title":"Int J Radiat Oncol"},{"key":"2209_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.phro.2019.02.002","volume":"9","author":"SU Tetar","year":"2019","unstructured":"Tetar SU, Bruynzeel AME, Lagerwaard FJ, et al. Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer. Phys Imaging Radiat Oncol. 2019;9:69\u201376.","journal-title":"Phys Imaging Radiat Oncol"},{"key":"2209_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jmir.2018.02.054","volume":"49","author":"C Hua","year":"2018","unstructured":"Hua C, Uh J, Krasin MJ, et al. Clinical implementation of magnetic resonance imaging systems for simulation and planning of pediatric radiation therapy. J Med Imaging Radiat Sci. 2018;49:153\u201363.","journal-title":"J Med Imaging Radiat Sci"},{"key":"2209_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.radonc.2019.11.025","volume":"145","author":"M Nachbar","year":"2020","unstructured":"Nachbar M, M\u00f6nnich D, Boeke S, et al. Partial breast irradiation with the 1.5 T MR-Linac: First patient treatment and analysis of electron return and stream effects. Radiother Oncol. 2020;145:30\u20135.","journal-title":"Radiother Oncol"},{"key":"2209_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.ijrobp.2019.11.406","volume":"106","author":"JE Vasmel","year":"2020","unstructured":"Vasmel JE, Charaghvandi RK, Houweling AC, et al. Tumor response after neoadjuvant magnetic resonance guided single ablative dose partial breast irradiation. Int J Radiat Oncol. 2020;106:821\u20139.","journal-title":"Int J Radiat Oncol"},{"key":"2209_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/jmrs.545","volume":"69","author":"A Berlangieri","year":"2022","unstructured":"Berlangieri A, Elliott S, Wasiak J, et al. Use of magnetic resonance image-guided radiotherapy for breast cancer: a scoping review. J Med Radiat Sci. 2022;69:122\u201333.","journal-title":"J Med Radiat Sci"},{"key":"2209_CR27","first-page":"66","volume":"6","author":"RT Morse","year":"2021","unstructured":"Morse RT, Doke K, Ganju RG, et al. Stereotactic body radiation therapy for apical lung tumors: dosimetric analysis of the brachial plexus and preliminary clinical outcomes. Pract Radiat Oncol. 2021;6:66.","journal-title":"Pract Radiat Oncol"},{"key":"2209_CR28","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.prro.2021.08.003","volume":"12","author":"K Jin","year":"2022","unstructured":"Jin K, Luo J, Wang X, et al. Symptoms related to brachial plexus neuropathy after supraclavicular irradiation and boost in breast cancer. Pract Radiat Oncol. 2022;12:e13\u201323.","journal-title":"Pract Radiat Oncol"},{"key":"2209_CR29","doi-asserted-by":"publisher","first-page":"6701","DOI":"10.1118\/1.4758068","volume":"39","author":"S Devic","year":"2012","unstructured":"Devic S. MRI simulation for radiotherapy treatment planning: MRI-simulation for RTP. Med Phys. 2012;39:6701\u201311.","journal-title":"Med Phys"},{"key":"2209_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.semradonc.2014.02.003","volume":"24","author":"P Dirix","year":"2014","unstructured":"Dirix P, Haustermans K, Vandecaveye V. The value of magnetic resonance imaging for radiotherapy planning. Semin Radiat Oncol. 2014;24:151\u20139.","journal-title":"Semin Radiat Oncol"},{"key":"2209_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1148\/radiol.2020202747","volume":"298","author":"R Otazo","year":"2021","unstructured":"Otazo R, Lambin P, Pignol J-P, et al. MRI-guided radiation therapy: an emerging paradigm in adaptive radiation oncology. Radiology. 2021;298:248\u201360.","journal-title":"Radiology"},{"key":"2209_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3322\/caac.21707","volume":"72","author":"WA Hall","year":"2022","unstructured":"Hall WA, Paulson E, Li XA, et al. Magnetic resonance linear accelerator technology and adaptive radiation therapy: an overview for clinicians. CA Cancer J Clin. 2022;72:34\u201356.","journal-title":"CA Cancer J Clin"},{"key":"2209_CR33","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s11060-021-03939-9","volume":"156","author":"BJ Geraghty","year":"2022","unstructured":"Geraghty BJ, Dasgupta A, Sandhu M, et al. Predicting survival in patients with glioblastoma using MRI radiomic features extracted from radiation planning volumes. J Neurooncol. 2022;156:579\u201388.","journal-title":"J Neurooncol"},{"key":"2209_CR34","doi-asserted-by":"publisher","first-page":"19830","DOI":"10.1038\/s41598-019-56185-5","volume":"9","author":"E Karami","year":"2019","unstructured":"Karami E, Soliman H, Ruschin M, et al. Quantitative MRI biomarkers of stereotactic radiotherapy outcome in brain metastasis. Sci Rep. 2019;9:19830.","journal-title":"Sci Rep"},{"key":"2209_CR35","first-page":"66","volume":"6","author":"S Fu","year":"2022","unstructured":"Fu S, Li Y, Han Y, et al. Diffusion-weighted magnetic resonance imaging-guided dose painting in patients with locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus concurrent chemoradiotherapy: a randomized, controlled clinical trial. Int J Radiat Oncol. 2022;6:66.","journal-title":"Int J Radiat Oncol"},{"key":"2209_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.645177","volume":"11","author":"M Li","year":"2021","unstructured":"Li M, Zhang Q, Yang K. Role of MRI-based functional imaging in improving the therapeutic index of radiotherapy in cancer treatment. Front Oncol. 2021;11: 645177.","journal-title":"Front Oncol"},{"key":"2209_CR37","doi-asserted-by":"publisher","first-page":"e2100366","DOI":"10.1200\/GO.21.00366","volume":"66","author":"S Srinivasan","year":"2022","unstructured":"Srinivasan S, Dasgupta A, Chatterjee A, et al. The promise of magnetic resonance imaging in radiation oncology practice in the management of brain, prostate, and GI malignancies. JCO Glob Oncol. 2022;66:e2100366.","journal-title":"JCO Glob Oncol"},{"key":"2209_CR38","doi-asserted-by":"publisher","first-page":"05TR01","DOI":"10.1088\/1361-6560\/aaaca4","volume":"63","author":"AM Owrangi","year":"2018","unstructured":"Owrangi AM, Greer PB, Glide-Hurst CK. MRI-only treatment planning: benefits and challenges. Phys Med Biol. 2018;63:05TR01.","journal-title":"Phys Med Biol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02209-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02209-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02209-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T07:09:34Z","timestamp":1675753774000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02209-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2209"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02209-4","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"assertion":[{"value":"8 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The need for approval was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The need for consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DMP: None. LH: None. LL: None. BC: holds industry partnership grants of Modus QA. DV: has received honoraria from Elekta. IK: None. HS: None. SS: has received honoraria from Bayer and Biogen. EL: None AL: None. SM: has received honoraria and research funding from Ipsen and AAA\/Novartis. GS: None. AS: is an advisor\/consultant with AbbVie, Merck, Roche, Varian (Medical Advisory Group), Elekta (Gamma Knife Icon), BrainLAB, and VieCure (Medical Advisory Board); is a Vice President of the International Stereotactic Radiosurgery Society (ISRS); has had past educational seminars with Elekta AB, Accuray Inc, Varian (CNS Teaching Faculty), BrainLAB, and Medtronic Kyphon; received research grants with Elekta AB and travel accommodations\/expenses from Elekta, Varian, and BrainLAB; is a co-chair of the AO Spine Knowledge Forum Tumor; and belongs to the Elekta MR-Linac Research Consortium and the Elekta Spine, Oligometastases and Linac-Based SRS Consortia. GC: None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}